[1] 中华医学会消化病学分会,中华医学会肝病学分会,中华医学会内镜学分会等.肝硬化门静脉高压食管胃静脉曲张出血的防治共识.中华消化杂志,2008,28(8):551-558. [2] Simonetto DA,Shah VH,Kamath PS. Primary prophylaxis of variceal bleeding. Clin Liver Dis,2014,18(2):335-345. [3] LamuraV,Abraldes JG,Raffa S, et a1. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol,2009,51(2):279-287. [4] Banares R,Moitinho E,Matilla A,et a1. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology,2002,36(6):1367-1373. [5] Tripathi D,Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liver Int,2014,34:655-667. [6] 徐晓琦,李民.丹参、心得安对门静脉高压症大鼠门静脉压力、肝纤维化指标及胃肠激素的影响. 浙江中医药大学学报,2010,34(3):312-313. [7] Hemstreet BA. Evaluation of carvedilol for the treatment of portal hypertension. Pharmacotherapy,2004,24(1):94-104. [8] Reiberger T,Ulbrich G,Ferlitsch A,et a1. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut,2013,62(11):1634-1641. [9] Akbas H,Ozden M,Kanko M,et al. Protective antioxidant effects of carvedilol in a rat model of ischaemia reperfusion injury. J Int Med Res,2005,33(5):528-536. [10] Rolo AP,Oliveira PJ,Moreno AJ,et a1. Chenodeoxy cholate induction of mitochondrial permeability transition pore is associated with increased membrane fluidity and cytochrome c release:protective role of carvedilol. Mitochondrion,2003,2(4):305-311. [11] Dulin B,Abraham WT. Pharmacology of carvedilol. Am J Cardiol,2004,93(9A):3B-6B. [12] Hamdy N,El-Demerdash E.New therapeutic aspect for carvedilol:Antifibrotic effects of carvedilol in chronic carbon tetrachloride induced liver damage. Toxicol Appl Pharmacol,2012,261(3):292-299. [13] Banares R,Moitinho E,Piqueras B,et al. Carvedilol,a new non selectiveve beta-blocker with intrinsic anti-alpha1-adrenergic activity,has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology,1999,30(1):79-83. [14] De BK,Das D,Sen S,et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol,2002,17:183-189. [15] Dhiraj T,Peter CH. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol,2010,22(8):905-911. [16] Sinagra E,Perricone G,D’Amico M,et al. Systematic review with meta-analysis:the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther,2014,39(6):557-568. [17] Hobolth L,Moller S,Gronbaek H,et al. Carvedilol or propranolol in portal hypertension A randomized comparison. Scand J Gastroenterol,2012,47(4):467-474. [18] Silkauskaite V,Pranculis A,Kupcinskas J,et al. Acute and 14-days hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. Medicina (Kaunas),2013,49(11):467-473. [19] Tfipathi D,Ferguson JW,Kochar N,et a1. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology,2009,50(3):825-833. [20] Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology,2010,51(6):2214-2218. [21] Hasnain AS,Zahid A,Javeria R,et a1. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage:A multicentre randomized controlled trial. J Hepatol,2014,60(4):757-764. [22] Serste T,Francoz C,Durand F,et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites:a cross-over study. J Hepatol,2011,55(4):794-799. [23] Bosch J. Carvedilol:theβ-blocker of choice for portal hypertension. Gut,2013,62(11):1529-1530. [24] Adrian JS,Sheila D,Peter CH,et a1. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol,2014, 61(5):1014-1019. [25] Merkel C,Marin R,Sacerdoti D,et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononit rate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology,2001,31(2):324-329. [26] Lin HC,Yang YY,Hou MC,et al. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol,2004,99(10):1953-1958. [27] Lo GH,Chen W C,Wang HM,et a1.Randomized,controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol, 2012,27(11):1681-1687. |